• Edifici M planta 1ª torre M1

      08193 Bellaterra (Cerdanyola del Vallès)

      España

    Aceptación de estudiantes de doctorado

    Se calcula con base en el n.º de publicaciones almacenadas en Pure y citas de Scopus
    1990 …2023

    Resultados de investigaciones por año

    Perfil personal

    Intereses en la investigación

    Lizcano’s Lab is interested in dissecting new cellular signaling pathways that control cancer cell proliferation and differentiation.  We collaborate with academics and Biopharma Companies to perform preclinical development of new anticancer drugs. Specifically, we are interested in deciphering the role of the new MAP kinase ERK5 (a MAP kinase) in cancer proliferation and survival. We are also interested in modulation of autophagy and endoplasmic reticulum (ER) stress as new strategies to tackle cancer

    We use two different perspectives to approach fundamental problems:

    a) Basic Research. Dissection of the mechanisms by ERK5 kinase (as well other kinases) exert a control on the proliferation and survival of tumor cells. We have contributed to propose new molecular mechanism for regulation of protein kinase Akt; discovered that tumor suppressor kinase LKB1 functions as a master kinase; or more recently, we have established a new mechanism by which ERK5 translocates to the nucleus and regulates the proliferation of tumor cells regardless of its enzymatic activity.

    b) Research directed to pharmacological intervention in cancer. We are involved in potentiating translational aspects of our resources. We actively collaborate with Ability Pharmaceuticals SL in the preclinical/clinical development of the new antitumor drug ABTL0812, which it is Clinical Trial Phase II to treat cancer patients with advanced endometrial and squamous NSCLC cancers (NCT02201823). We have discovered a new cellular signaling pathway by which ABTL0812 exerts its antitumor action: by altering the sphingolipidoma of cancer cells, ABTL0812 induces a sustained activation of ER stress and UPR, as well as inhibition of the Akt/mTORC1, which ultimately results in activation of cytotoxic autophagy. Finally, we actively collaborate with other academic laboratories characterizing new ERK5 inhibitors with anticancer activity.


    CURRENT WORK

    1) Role of MAP kinase ERK5 in cancer cell proliferation and survival (neuroblastoma and endometrial cancer)

    2) Preclinical development of new drugs for cancer therapy. Antitumoral drugs that exert their action by activating cytotoxic autophagy. New ERK5 inhibitors with anti-cancer activity.



    Experiencia relacionada con los ODS de las Naciones Unidas

    En 2015, los estados miembros de las Naciones Unidas acordaron 17 Objetivos de Desarrollo Sostenible (ODS) para erradicar la pobreza, proteger el planeta y garantizar la prosperidad para todos. El trabajo de esta persona contribuye al logro de los siguientes ODS:

    • ODS 3: Salud y bienestar

    Educación/cualificación académica

    Doctor/a, Ciencias Biológicas, Universitat Autònoma de Barcelona (UAB)

    Fecha de beca: 20 dic 1994

    Máster, Master Bioqquimica i Biologia Molecular, Universitat Autònoma de Barcelona (UAB)

    Fecha de beca: 20 sept 1989

    Licenciado/a, Ciencias Biológicas, Universitat Autònoma de Barcelona (UAB)

    Fecha de beca: 1 jul 1987

    Puestos externos a la institución

    MRC Research Associate, MRC Protein Phosphorylation Unit, University of Dundee (UK)

    1 nov 200031 ago 2004

    Post-doctoral researcher, Department of Biochemistry, Trinty College Dublin (Ireland)

    1 jul 199530 mar 1996

    Professor ajudant de Facultat (2na etapa), Dept Bioquimica, Facultad de Medicina

    12 ene 199514 sept 1998

    Prof. ayudante de Facultad (1ª etapa), Universitat Autònoma de Barcelona (UAB)

    1 feb 199211 ene 1995

    Prof. ayudante de escuela Univ., Dept Bioquimica, Facultad de Medicina

    1 sept 19911 feb 1992

    Huella digital

    Profundizar en los temas de investigación en los que Jose Miguel Lizcano de Vega está activo. Estas etiquetas de temas provienen de las obras de esta persona. Juntos, forma una huella digital única.
    • 1 Perfiles similares

    Colaboraciones y áreas de investigación principales de los últimos cinco años

    Colaboración externa reciente a nivel de país/territorio. Para consultar los detalles, haga clic en los puntos o